Metformin Vicious Cycle

Skeletal muscle is responsible for roughly 80% of the work your body does to clear glucose out of your bloodstream, and that number comes from a 1981 study by DeFronzo measuring insulin-mediated glucose disposal directly. Not your liver. Not your fat tissue. Your muscle. Which means when muscle mass drops, the primary system your body uses to manage blood sugar shrinks with it, and that is how low muscle mass and insulin resistance end up so tightly connected.

That connection is the map. Keep it in mind, because everything else in this article is about what happens when a common drug interacts with it.

Metformin works by inhibiting something called Complex I, which is the first protein complex in the electron transport chain inside your mitochondria, the part of the energy production process where your cells use oxygen to generate ATP. When Complex I gets inhibited, the ratio of AMP to ATP inside the cell rises, meaning the cell is detecting an energy shortage, and that triggers something called AMPK, which stands for AMP-activated protein kinase and functions essentially as a cellular low-fuel alarm.

When AMPK activates, it does several things at once. One of them is pushing glucose transporter proteins to the surface of muscle cells so glucose can enter without needing insulin. That is the mechanism behind why metformin lowers blood sugar, and it genuinely works for that purpose.

But AMPK does not stop there.

AMPK also suppresses something called mTOR, specifically the mTORC1 complex, which is the primary pathway your body uses to build new muscle protein after training. It does this through two separate mechanisms. First, AMPK phosphorylates a protein called TSC2, which acts as a brake on mTOR signaling. Second, AMPK phosphorylates a protein called Raptor, which is a structural component of mTORC1 itself, and that directly inhibits the complex. Research from 2002 found that AMPK activation reduces muscle protein synthesis through this mTOR suppression, which means the same signal that makes metformin effective at lowering blood sugar is simultaneously telling your muscle to stop growing.

Think of it like a building with a gas pedal and a brake wired to the same switch. Pressing the switch moves you forward on blood sugar but applies the brake on muscle construction at the same time.

This would be theoretical concern if not for what happened in a 2019 randomized controlled trial called the MASTERS trial. Ninety-four adults over the age of 65 were assigned to either metformin or a placebo for 14 weeks while doing a structured resistance training program. The researchers going into the trial actually expected metformin to help with muscle growth, because the drug has anti-inflammatory properties and inflammation is known to interfere with muscle repair after exercise. The result was the opposite. The placebo group gained significantly more muscle mass and more muscle density than the metformin group over the same training protocol. Same workouts, different drug, measurably less muscle.

A separate 2019 trial by Konopka and colleagues looked at what metformin does to mitochondrial adaptations specifically. One of the most important effects of regular exercise is that it improves how well your mitochondria function, and that mitochondrial improvement is a major mechanism behind how exercise increases insulin sensitivity independent of weight loss. That trial found metformin blocked those mitochondrial adaptations. The exercise happened, but the cellular upgrade that exercise normally triggers did not.

So now you can see the full shape of the problem.

You lose muscle mass, which reduces the tissue responsible for clearing blood sugar, which leads to insulin resistance. You get prescribed a drug that lowers blood sugar by activating AMPK. AMPK suppresses mTOR. mTOR suppression blunts the muscle growth response to resistance training. You stay with lower muscle mass than you would have built otherwise. The root cause of the insulin resistance, insufficient muscle tissue, does not improve the way it could.

That is the cycle. Not a metaphor. A literal chain of mechanisms, each one linking to the next.

The conversation worth having with your doctor is not whether metformin works at lowering blood sugar, because it does. The conversation is whether the mechanism by which it works creates a secondary effect that keeps the underlying problem in place, and whether resistance training combined with the metabolic changes training produces might address the root defect more directly than a drug that partially blocks the adaptation you are trying to build.

DeFronzo's 2009 Banting Lecture described muscle insulin resistance as a core defect in type 2 diabetes, not a downstream consequence but a primary driver. If the tissue that does 80% of the work is both the source of the problem and the solution to it, then anything that limits your ability to build and maintain that tissue deserves to be part of the clinical conversation.

Resistance training builds the muscle that clears glucose. That muscle becoming more insulin-sensitive is not a side effect of training. It is the mechanism. And if you are taking a drug that partially suppresses the cellular pathway responsible for building that muscle, you are working against the most direct route back to metabolic health at exactly the moment you are trying hardest to get there.

---

References

1. DeFronzo RA et al. (1981). "The effect of insulin on the disposal of intravenous glucose." J Clin Invest. 68(6):1468-1474. Finding: Skeletal muscle responsible for approximately 80% of insulin-mediated glucose disposal. PMID: 7033285
2. DeFronzo RA (2009). "From the triumvirate to the ominous octet." Banting Lecture. Diabetes Care. 32(Suppl 2):S157-S163. Finding: Muscle insulin resistance is a core defect in type 2 diabetes. PMID: 19875544
3. Walton RG et al. (2019). "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: The MASTERS trial." Aging Cell. 18(6):e13039. Finding: n=94, adults 65+, placebo group gained significantly more muscle. PMID: 31557380
4. Konopka AR et al. (2019). "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 18(1):e12880. Finding: Metformin blocked exercise-induced mitochondrial improvements. PMID: 30548390
5. Drewe J et al. (2026). "Metformin: Mechanism of action." Pharmacol Rev. Finding: Complex I inhibition activates AMPK. PMID: 41389439
6. Inoki K et al. (2003). Nat Cell Biol. Finding: AMPK phosphorylates TSC2, suppressing mTOR. PMID: 12847286
7. Gwinn DM et al. (2008). Mol Cell. Finding: AMPK phosphorylates Raptor to suppress mTORC1. PMID: 18439900
8. Bolster DR et al. (2002). J Biol Chem. Finding: AMPK activation reduces muscle protein synthesis through mTOR suppression. PMID: 12351658

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness